influence of genetics on tacrolimus in patients with kidney transplantation in tertiary care centre
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Patients with End stage renal disease whoever undergone renal transplantation
- Registration Number
- CTRI/2017/09/009828
- Lead Sponsor
- Dr G Sirisha
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
1.Patients of either gender, aged between 18-70 years and have undergone renal transplantation for end stage renal disease.
2.Patients on stable dose of tacrolimus (2-5 mg), with no change in the dose for at least two weeks.
3.Patients willing to give written informed consent
Exclusion Criteria
1.Patients with co-morbid conditions such as hepatic insufficiency
2.Patients on other drugs which are likely to interact with immunosuppressive drugs.
3.Patients who suffered from gastrointestinal disease, liver disease or other disorders that may alter the absorption of tacrolimus.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. To determine the genotype of the patients <br/ ><br> 2.To study trough concentration C0/ dose of tacrolimus in relation to the genotype of the patients <br/ ><br>Timepoint: 12 months
- Secondary Outcome Measures
Name Time Method 1.To monitor for graft status <br/ ><br>2.To observe incidence of infections and other adverse drug reactions. <br/ ><br>Timepoint: 12 months